This chart shows the companies which have received the most New Patient Population exclusivities in the past five years.
New Patient Populations are one of the categories for which the FDA grants three years of exclusivity for ‘New Clinical Investigations.’
Alternate categories worth of three years of protection include identifying a New Combination,
New Product, or New Strength.
The companies with the most New Patient Populations drugs are:
- Mylan Speciality Lp
- Allergan
- Astrazeneca
- Bristol Myers Squibb
- Cumberland
- Fougera
- Gilead Sciences Inc
- Hoffmann La Roche
- Horizon Pharma Usa
- Ipr
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
